

NUS scientists harness AI platform for advanced cancer

03 September 2018 | News

The new study demonstrates that CURATE.AI can optimize multi-drug regimens.



A translational research team led by the National University of Singapore (NUS) has harnessed CURATE.AI, a powerful artificial intelligence (AI) platform, to successfully treat a patient with advanced cancer, completely halting disease progression. This new development represents a big step forward in personalized medicine.

During the clinical study, a patient with metastatic castration-resistant prostate cancer (MCRPC) was given a novel drug combination consisting of investigational drug ZEN-3694 and enzalutamide, an approved prostate cancer drug. The research team successfully utilized CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.

According to the scientific team, CURATE.AI is applicable to all diseases and all patients, and a first generation of the platform was previously validated in the clinic for single drug optimization in post-transplant immunosuppression. This new study demonstrates that CURATE.AI can optimize multi-drug regimens.

The CURATE.AI team expects to broadly deploy the platform for the prevention of transplant rejection, adult and pediatric cancers, cardiovascular medicine, diabetes management, infectious diseases, and many other applications.